玻璃体内注射阿柏西普、贝伐珠单抗和雷珠单抗的全身药代动力学与药效学
这项前瞻性、开放标签、非随机临床试验纳入151例新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿或视网膜静脉阻塞患者,比较三种抗血管内皮生长因子(VEGF)药物玻璃体内注射后的全身药代动力学与血浆游离VEGF水平变化,发现贝伐珠单抗全身暴露最高、雷珠单抗最低,阿柏西普降低血浆游离VEGF幅度最大、雷珠单抗最小。
要点
- 贝伐珠单抗全身暴露最高,其次为阿柏西普,雷珠单抗最低。
- 雷珠单抗从血流清除比贝伐珠单抗或阿柏西普更快。
- 阿柏西普降低血浆游离VEGF幅度最大,雷珠单抗最小。
核心结论
- 三种抗VEGF治疗的全身药代动力学存在明显差异。
- 血浆游离VEGF水平的降低一般与循环抗VEGF药物水平升高相关,其中阿柏西普降低游离VEGF幅度最大、雷珠单抗最小。
研究设计与样本
- 前瞻性、开放标签、非随机临床试验,纳入151例新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿或视网膜静脉阻塞患者。
- 患者为抗VEGF初治或至少4个月未接受抗VEGF治疗,接受3次每月一次玻璃体内注射阿柏西普2.0 mg、贝伐珠单抗1.25 mg或雷珠单抗(年龄相关性黄斑变性/视网膜静脉阻塞0.5 mg,糖尿病黄斑水肿0.3 mg)。
- 主要结局指标为首次和第三次注射后的血清药代动力学和血浆游离VEGF浓度。
主要发现
- 在年龄相关性黄斑变性/糖尿病黄斑水肿/视网膜静脉阻塞中,每种药物的全身暴露均以贝伐珠单抗最高,其次为阿柏西普,雷珠单抗最低。
- 雷珠单抗从血流清除比贝伐珠单抗或阿柏西普更快。
- 阿柏西普治疗使血浆游离VEGF相对基线降低幅度最大,而雷珠单抗治疗降低幅度最小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naïve or had not received anti-VEGF for ≥4 months. Patients received 3 monthly intravitreal injections of aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab (0.5 mg for AMD/RVO, 0.3 mg for DME). The main outcome measures were serum PKs and plasma free-VEGF concentrations after the first and third injections. RESULTS: A total of 151 patients were included. In AMD/DME/RVO, systemic exposure to each drug was highest with bevacizumab, then aflibercept, and lowest with ranibizumab. Ranibizumab cleared from the bloodstream more quickly than bevacizumab or aflibercept. Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF. CONCLUSION: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.
引用
- Avery RL, Castellarin AA, Steinle NC, et al. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina. 2017. PMID: 28106709. doi:10.1097/IAE.0000000000001493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。